China Pharma Holdings (CPHI) AI Stock Analysis

• Market Cap: $7.24M
• Dividend Yield: N/A
• Average Volume (3M): 1.01M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.00
• Revenue Growth: -35.41%
• EPS Growth: 72.84%
• Country: US
• Employees: 231
• Sector: Healthcare
• Sector Strength: 76
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.27
• Shares Outstanding: 32,619,110
• 10 Day Avg. Volume: 462,959
• 30 Day Avg. Volume: 1,006,286
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.82
• Price to Cash Flow (P/CF): N/A
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

China Pharma Holdings' stock score is low due to significant financial challenges, including high debt and negative cash flow trends. The technical analysis is neutral, but the negative P/E ratio suggests overvaluation concerns. Overall, the stock's financial instability and lack of valuation appeal contribute to the low score.

China Pharma Holdings Business Overview & Revenue Model

Company Description

China Pharma Holdings, Inc. (CPHI) is a pharmaceutical company engaged in the development, manufacture, and marketing of a wide variety of pharmaceutical products. The company's primary focus is on the therapeutic areas of cardiovascular diseases, central nervous system disorders, infectious diseases, and other critical medical needs. With a strong emphasis on quality and innovation, China Pharma Holdings aims to meet the growing demand for effective and affordable healthcare solutions in China and other emerging markets.

How the Company Makes Money

China Pharma Holdings generates revenue primarily through the production and sale of pharmaceutical products. The company's revenue model is based on the commercialization of its diverse portfolio of drugs, which includes both prescription and over-the-counter medications. Key revenue streams include sales to hospitals, pharmacies, and other healthcare institutions. Additionally, China Pharma Holdings may engage in strategic partnerships with other pharmaceutical companies to expand its product offerings and market reach, thereby enhancing its revenue potential. The company's earnings are influenced by factors such as product pricing, market demand, regulatory approvals, and its ability to innovate and introduce new products to the market.

China Pharma Holdings Financial Statement Overview

Summary

China Pharma Holdings faces significant financial challenges, characterized by declining revenue, persistent losses, and negative cash flows. High leverage and decreasing shareholder equity add to the financial instability. The company must address its cost structure and improve cash flow management to stabilize its financial position.

Income Statement

The company has been consistently operating at a loss, with negative gross profit, EBIT, and net income in recent periods. Revenue has been declining from 2020 to the TTM (Trailing-Twelve-Months) period. The gross profit margin is negative due to higher costs relative to revenue, and there is a consistent decline in EBIT and EBITDA margins.

Balance Sheet

The debt-to-equity ratio is concerning, indicating high leverage, though it has improved slightly in the TTM period. The equity ratio is relatively stable, but the company's declining equity position and high total liabilities pose financial risks. ROE is negative, reflecting operating losses.

Cash Flow

Operating and free cash flows are negative, indicating cash burn. The cash flow to net income ratios are not favorable, further highlighting financial strains. Free cash flow has been declining, suggesting challenges in generating cash.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
5.54M	7.01M	8.10M	9.64M	10.87M	10.92M
	Gross Profit
-2.07M	-281.08K	-493.92K	349.27K	1.95M	1.48M
	EBIT
-4.58M	-2.75M	-3.55M	-3.12M	-2.46M	-3.39M
	EBITDA
-1.70M	8.44K	-837.69K	230.34K	106.85K	-17.45M
	Net Income Common Stockholders
-4.74M	-3.08M	-10.22M	-3.94M	-3.16M	-21.02M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
4.78M	1.42M	2.03M	4.86M	957.65K	1.07M
	Total Assets
108.15M	16.47M	17.78M	22.65M	21.12M	22.24M
	Total Debt
3.80M	4.63M	8.76M	12.49M	7.43M	4.55M
	Net Debt
-981.24K	3.21M	6.73M	7.63M	6.47M	3.48M
	Total Liabilities
10.82M	9.01M	13.49M	16.63M	13.11M	13.00M
	Stockholders Equity
97.34M	7.45M	4.29M	6.02M	8.00M	9.24M
Cash Flow		Free Cash Flow
-750.55K	-711.20K	-811.51K	-687.89K	-909.57K	472.31K
	Operating Cash Flow
-727.16K	-699.69K	-409.55K	-249.84K	-42.26K	608.31K
	Investing Cash Flow
-23.39K	-11.52K	-401.96K	-438.06K	-867.31K	-136.00K
	Financing Cash Flow
50.93K	73.14K	-1.77M	4.60M	624.18K	-1.73M

China Pharma Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.22
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CPHI, the sentiment is Negative. The current price of 0.22 is below the 20-day moving average (MA) of 0.25, below the 50-day MA of 0.23, and below the 200-day MA of 0.22, indicating a bearish trend. The MACD of 0.01 indicates Negative momentum. The RSI at 53.19 is Neutral, neither overbought nor oversold. The STOCH value of 56.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CPHI.

China Pharma Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	48 Neutral	$6.36B	1.09	-49.92%	2.63%	17.17%	0.95%
XBIO	41 Neutral	$3.99M	―	-50.12%	―	-1.56%	5.01%
SBFM	39 Underperform	$4.25M	―	-22.97%	―	44.75%	86.42%
CPHI	32 Underperform	$7.24M	―	-61.58%	―	-35.41%	72.84%

China Pharma Holdings Corporate Events

China Pharma Holdings Announces Reverse Stock Split

On April 4, 2025, China Pharma Holdings announced a 1-for-10 reverse stock split set to take effect on April 15, 2025. This move, authorized by the Board and stockholders, will consolidate every 10 shares into one, affecting all shareholders uniformly without altering their percentage interest in the company.